News & Updates

Show Multimedia Only

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026 by

The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026

Mediterranean, plant-based diets vital in MASLD management

12 Jan 2026 by

Dietary interventions continue to provide benefits in the management of chronic liver diseases and serve as a valuable addition to pharmacotherapy options available, reports a study.

Mediterranean, plant-based diets vital in MASLD management

12 Jan 2026

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026 by

A recent study has demonstrated the long-term safety of mirikizumab in patients with moderate to severe active ulcerative colitis (UC), with no new significant safety concerns.

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

In addition to improving glycaemic control, the use of SGLT2 inhibitors also appears to reduce mortality, hospitalization, cardiovascular events, and liver complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

Which social determinant predicts MASLD prevalence, severity?

08 Jan 2026

Among several social determinants of health (SDOHs), diet quality is most consistently associated with disease prevalence and severity in metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Which social determinant predicts MASLD prevalence, severity?

08 Jan 2026

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

18 Dec 2025 by

The LIVE-SMART trial presented at AASLD 2025 shows that lactulose and Tai chi may prevent falls in individuals with cirrhosis and portal hypertension.

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

18 Dec 2025

Tinengotinib shows promising activity against cholangiocarcinoma

16 Dec 2025

In patients with cholangiocarcinoma with FGFR2 fusions that progressed following FGFR inhibitor therapy, tinengotinib has demonstrated potential antitumour activity in a phase II study.

Tinengotinib shows promising activity against cholangiocarcinoma

16 Dec 2025

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

15 Dec 2025 by

The post hoc subgroup analysis of the phase III MITIGATE trial shows the benefit of the humanized monoclonal anti-CD19 antibody inebilizumab in adults with IgG4-related disease (IgG4-RD) with pancreas, bile duct, and liver involvement at baseline.

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

15 Dec 2025

Steatotic liver disease common in people with metabolic, alcohol risk factors

13 Dec 2025 by

Steatotic liver disease (SLD) appears to be highly prevalent among individuals with cardiometabolic or alcohol risk factors, while elevated liver stiffness and advanced liver fibrosis are not uncommon, reports a recent study.

Steatotic liver disease common in people with metabolic, alcohol risk factors

13 Dec 2025

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

News & Updates

Showing Hepatology articles

Showing

Specialty:

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Mediterranean, plant-based diets vital in MASLD management

Mediterranean, plant-based diets vital in MASLD management

Long-term use of mirikizumab does not raise new safety signals

Long-term use of mirikizumab does not raise new safety signals

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

Which social determinant predicts MASLD prevalence, severity?

Which social determinant predicts MASLD prevalence, severity?

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

Tinengotinib shows promising activity against cholangiocarcinoma

Tinengotinib shows promising activity against cholangiocarcinoma

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

Steatotic liver disease common in people with metabolic, alcohol risk factors

Steatotic liver disease common in people with metabolic, alcohol risk factors

Rifaximin does not improve survival in severe cirrhosis

Rifaximin does not improve survival in severe cirrhosis